Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Opening of $500,000 Line of Credit

20th Aug 2025 07:00

RNS Number : 9849V
MyCelx Technologies Corporation
20 August 2025
 

20 August 2025

 

MYCELX Technologies Corporation

("MYCELX" or the "Company")

 

Opening of $500,000 Line of Credit

 

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, is pleased to announce that it has opened a line of credit ("LOC") with TriState Capital Bank which will allow the Company to access up to $500,000.

 

The proceeds will enable MYCELX to increase funds available for sales and marketing, trial equipment, and bridging project accounts receivable as the Company expands and accelerates its reach to meet the growing demand for its technology in PFAS remediation and Produced Water treatment.

 

The LOC has the following terms: Floating rate basis Adjusted One Month Term of the Secured Overnight Financing Rate (SOFR) plus 1.5% margin, however the rate will never be below 2.49%. As of 15 August 2025, the SOFR rate is 4.36%. The LOC has been personally guaranteed by MYCELX's Chief Executive Officer Connie Mixon for no cost to the Company or otherwise.

 

Connie Mixon, CEO, commented:

 

"In securing this new LOC, MYCELX is placing itself in a stronger position to pursue its robust opportunity pipeline and further capitalize on recent successful trials and installations. The LOC provides flexibility for the Company to increase marketing spend and trials while bridging milestone projects to completion. The Company believes recognition of the performance of its technology globally is accelerating and targeted marketing in the PFAS and Produced Water markets will positively impact conversion of RFQs to contracts."

 

The provision of the guarantee constitutes a related party transaction under AIM Rule 13 of the AIM Rules for Companies. The independent directors, being Tom Lamb, Hal Alper and Andre Schnabl, having consulted the Company's Nominated Adviser, Cavendish Capital Markets Limited, consider the terms of the guarantee to be fair and reasonable insofar as shareholders are concerned.

 

 

For further information, please contact:

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)

Giles Balleny / Callum Davidson (Corporate Finance)

Jamie Anderson (Corporate Broking)

Jasper Berry / Michael Johnson (Sales)

 

 

 

Tel: +44 20 7220 0500

 

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPKCBQKBKBCFD

Related Shares:

Mycelx Di
FTSE 100 Latest
Value9,216.82
Change-38.68